Phase II Minimal Residual Disease Study of Selective Estrogen Receptor Degrader Imlunestrant With Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Abemaciclib in Patients With ER+ Breast Cancer (MIRI)
Latest Information Update: 24 Aug 2026
At a glance
- Drugs Abemaciclib (Primary) ; Imlunestrant (Primary)
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Pharmacodynamics
- Acronyms MIRI; MIRI Trial
Most Recent Events
- 20 Aug 2026 Status changed from not yet recruiting to recruiting.
- 10 Nov 2025 Planned End Date changed from 30 Sep 2031 to 30 Apr 2031.
- 10 Nov 2025 Planned primary completion date changed from 30 Sep 2030 to 30 Apr 2030.